BioHabana 2022: Preventive and Immunotherapeutic Strategies Against COVID-19 and Cancer in Cuba
Iraldo Bello Rivero(Centro de Ingeniería Genética y Biotecnología), Gerardo Guillén(Hunan City University), Ana Aguilera‐Barreto(Centro de Ingeniería Genética y Biotecnología), Verena L. Muzio‐González(Centro de Ingeniería Genética y Biotecnología), Francisco Hernández‐Bernal(Centro de Ingeniería Genética y Biotecnología), Dagmar García-Rivera(Finlay Institute), María del Carmen Domínguez-Horta(Centro de Ingeniería Genética y Biotecnología), Hugo Nodarse-Cuní, Yanelys Morera Díaz(Centro de Ingeniería Genética y Biotecnología), Circe Mesa-Pardillo(Center of Molecular Immunology (Cuba)), Tania Crombet(Center of Molecular Immunology (Cuba)), Zaima Mazorra-Herrera(Center of Molecular Immunology (Cuba)), Dania Vázquez‐Blomquist(Centro de Ingeniería Genética y Biotecnología)
Cited by 0
Related Papers
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
|Frontiers in Endocrinology|2020|134